Other Guidelines | Page 43 | European Cystic Fibrosis Society (ECFS)

Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?

Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis

Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis

Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial

Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis

Meconium Ileus due to GUCY2C gene mutations in three unrelated South Indian families

MyCyFapp clinical trial sub-study on change in PERT and fat absorption

Attitudes of Pain and Opioids Prescription Practices in U.S. Cystic Fibrosis Centers

Alpha-1 Antitrypsin for Cystic Fibrosis Complicated by Severe Cytokinemic COVID-19

Elevated blood glucose during exacerbations of cystic fibrosis lung disease is associated with poor recovery of lung function.

first
previous
…
39
40
41
42
43
44
45
46
47
…
next
last